Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
4 hedge funds and large institutions have $4 invested in Sorrento Therapeutics, Inc. in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 3 closing their positions.
20% less funds holding
Funds holding: 5 → 4 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
94% less capital invested
Capital invested by funds: $66 → $4 (-$62)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KWA
Kingswood Wealth Advisors
San Diego,
California
|
-$32 |
| 2 |
LCM
Lattice Capital Management
Kirkland,
Washington
|
-$26 |
| 3 |
HAG
HighPoint Advisor Group
Downers Grove,
Illinois
|
-$4 |
SRNE Hedge Fund Activity: Q1 2025 in Review
4 of the 7,470 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q1 2025, worth a combined $4 — down 94% from $66 a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SRNE and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest seller was Kingswood Wealth Advisors, exiting entirely with an estimated $32 sold.
- 4 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q1 2025, down from 5 in Q4 2024.
- Funds reported $4 of Sorrento Therapeutics, Inc. stock for Q1 2025, down 94% quarter-over-quarter.
- 2 funds opened new Sorrento Therapeutics, Inc. positions in Q1 2025 and 3 closed out, a net change of -1 holder.
- The largest Sorrento Therapeutics, Inc. seller in Q1 2025 was Kingswood Wealth Advisors, an estimated $32 sold.
Based on aggregated 13F filings for Q1 2025.